Pruritus

Dermatology
4
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Precision BioSciences
1 program
1
ProvasePhase 41 trial
Active Trials
NCT00782054Completed23Est. Apr 2008
Regeneron
RegeneronTARRYTOWN, NY
2 programs
1
1
Dupilumab 300Mg Solution for InjectionPhase 21 trial
REGN846Phase 1/21 trial
Active Trials
NCT01605708Terminated19Est. Apr 2013
NCT04256759Completed9Est. Sep 2024
VP
Vanda PharmaceuticalsWASHINGTON, DC
1 program
1
VLY-686Phase 11 trial
Active Trials
NCT01919944Completed12Est. Nov 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Precision BioSciencesProvase
RegeneronDupilumab 300Mg Solution for Injection
RegeneronREGN846
Vanda PharmaceuticalsVLY-686

Clinical Trials (4)

Total enrollment: 63 patients across 4 trials

Evaluation of Post Burn Rehabilitation Population for Itch Control

Start: Sep 2006Est. completion: Apr 200823 patients
Phase 4Completed
NCT04256759RegeneronDupilumab 300Mg Solution for Injection

Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

Start: Sep 2020Est. completion: Sep 20249 patients
Phase 2Completed

Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis

Start: Jun 2012Est. completion: Apr 201319 patients
Phase 1/2Terminated

Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P

Start: Aug 2013Est. completion: Nov 201312 patients
Phase 1Completed

Related Jobs in Dermatology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space